TARA
Protara Therapeutics, Inc.
Biotechnology
Market Cap$288M
5Y Perf.-90.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TARA vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
TARA vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TARA | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $288M | $2.57B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-57M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $3M | $1.28B |
| Cash & Equiv. | $50M | $434M |
TARA vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TARA
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Protara Therapeutic… (TARA) | 100 | 9.9 | -90.1% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TARA vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TARA leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
TARA
Protara Therapeutics, Inc.
The Income Pick
TARA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.16
- EPS growth 38.2%
- Lower volatility, beta 1.16, Low D/E 1.7%, current ratio 14.58x
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Long-Run Compounder
RARE is the clearest fit if your priority is long-term compounding.
- -59.4% 10Y total return vs TARA's -98.3%
- 20.1% revenue growth vs TARA's -28.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs TARA's -28.9% |
| Quality / Margins | TARA | 3.0% margin vs RARE's -91.0% |
| Stability / Safety | TARA | Beta 1.16 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TARA | +60.3% vs RARE's -21.8% |
| Efficiency (ROA) | TARA | -33.8% ROA vs RARE's -45.8%, ROIC -60.9% vs -89.4% |
TARA vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
TARA vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTARALAGGINGRARE
RAREUltragenyx Pharmaceut…
1leads
TARAProtara Therapeutics,…
4leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TARA1/1
Valuation MetricsMultiples, price ratios, and targets
RARE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TARA6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TARA4/6
Risk & VolatilityBeta, volatility, and downside exposure
TARA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TARA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RARE and TARA operate at a comparable scale, with $669M and $0 in trailing revenue.
| Metric | TARAProtara Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$64M | -$536M |
| Net IncomeAfter-tax profit | -$57M | -$609M |
| Free Cash FlowCash after capex | -$56M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +20.8% | -17.2% |
TARA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | TARAProtara Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $288M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $241M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -4.01x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.82x |
| Price / BookPrice ÷ Book value/share | 1.17x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
TARA leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
TARA delivers a -36.4% return on equity — every $100 of shareholder capital generates $-36 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs TARA's 3/9, reflecting mixed financial health.
| Metric | TARAProtara Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -36.4% | -6.1% |
| ROA (TTM)Return on assets | -33.8% | -45.8% |
| ROICReturn on invested capital | -60.9% | -89.4% |
| ROCEReturn on capital employed | -35.0% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$46M | $842M |
| Cash & Equiv.Liquid assets | $50M | $434M |
| Total DebtShort + long-term debt | $3M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -40.98x | -14.49x |
TARA leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TARA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TARA five years ago would be worth $5,463 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, TARA leads with a +60.3% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors TARA at 20.2% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | TARAProtara Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -0.2% | +10.7% |
| 1-Year ReturnPast 12 months | +60.3% | -21.8% |
| 3-Year ReturnCumulative with dividends | +73.8% | -44.5% |
| 5-Year ReturnCumulative with dividends | -45.4% | -77.2% |
| 10-Year ReturnCumulative with dividends | -98.3% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +20.2% | -17.8% |
TARA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
TARA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TARA is the less volatile stock with a 1.16 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TARA currently trades 68.7% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TARAProtara Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 1.42x |
| 52-Week HighHighest price in past year | $7.82 | $42.37 |
| 52-Week LowLowest price in past year | $2.77 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +68.7% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 60.1 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 741K | 1.8M |
TARA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TARA as "Buy" and RARE as "Buy". Consensus price targets imply 123.5% upside for TARA (target: $12) vs 97.1% for RARE (target: $52).
| Metric | TARAProtara Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $12.00 | $51.50 |
| # AnalystsCovering analysts | 5 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TARA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RARE leads in 1 (Valuation Metrics).
Best OverallProtara Therapeutics, Inc. (TARA)Leads 4 of 6 categories
Loading custom metrics...
TARA vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TARA or RARE a better buy right now?
Analysts rate Protara Therapeutics, Inc.
(TARA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TARA or RARE?
Over the past 5 years, Protara Therapeutics, Inc.
(TARA) delivered a total return of -45. 4%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: RARE returned -59. 4% versus TARA's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TARA or RARE?
By beta (market sensitivity over 5 years), Protara Therapeutics, Inc.
(TARA) is the lower-risk stock at 1. 16β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 22% more volatile than TARA relative to the S&P 500.
04Which is growing faster — TARA or RARE?
On earnings-per-share growth, the picture is similar: Protara Therapeutics, Inc.
grew EPS 38. 2% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TARA or RARE?
Protara Therapeutics, Inc.
(TARA) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TARA leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TARA or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TARA or RARE better for a retirement portfolio?
For long-horizon retirement investors, Protara Therapeutics, Inc.
(TARA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16)). Both have compounded well over 10 years (TARA: -98. 3%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TARA and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TARA is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.